# **Munich Cancer Registry**



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

# **Cancer statistics: Baseline statistics**

# **BNET: Lung neuroend. tumor**

Year of diagnosis	1998-2011
Patients	477
Diseases	478
Creation date	04/02/2013
Export date	01/03/2013
Population	4.5 m



http://www.tumorregister-muenchen.de/en/facts/base/base\_hBNETE.pdf

# Global Statements about the statistics on the Internet – Baseline Statistics (grey button —), Survival (red button —)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut<sup>#</sup>, with a total of 4.5 million inhabitants, account for the frequency of cancer diseases<sup>##</sup> and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases\*\*\*\* are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.


The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, April 2013

- Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2011 are incorporated into these analyses.
- Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.



### ICD-10 codes used for specifying cancer site

Code	Description
C33.9	Trachea
C34.0	Main bronchus
C34.1	Upper lobe
C34.2	Middle lobe
C34.3	Lower lobe
C34.8	Overlapping lesion of lung
C34.9	Lung, NOS

#### ICD-O-3 codes (morphology) used for specifying cancer site

Code	Description
8013/3 8240/3 8249/3	Large cell neuroendocrine carcinoma Typical carcinoid Atypical carcinoid tumor

#### Reference:

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC, Lyon (2004).

#### **INCIDENCE**

Table 1

Patient cohorts by year of diagnosis including DCO cases and multiple primaries, and with proportion of deaths and active follow-up

				Prop.		Prop.
		DCO	Prop.	mult.	Prop.	actively
Year of	Cases #	cases	DCO	primaries	deaths	followed
diagnosis	n	n	%	96	%	%
1998	12			16.7	41.7	83.3
1999	22			27.3	54.5	100.0
2000	21			33.3	47.6	100.0
2001	21			23.8	61.9	95.2
2002	25			24.0	36.0	96.0
2003	22			13.6	40.9	100.0
2004	29			17.2	37.9	93.1
2005	28			25.0	32.1	89.3
2006	28			14.3	28.6	89.3
2007	41			17.1	46.3	82.9 ##
2008	60			31.7	38.3	71.7
2009	56			26.8	33.9	55.4
2010	47			27.7	42.6	95.7
2011	66			18.2	24.2	81.8 ###
1998-2011	478			23.2	38.3	84.3

<sup>#</sup> The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

<sup>##</sup> Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

<sup>###</sup> Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

base\_hBNETE.pdf

Table 1a

Patient cohorts by year of diagnosis and gender including DCO cases

Year of diagnosis	All n	Males	Females n	Prop. males	
1998	12	6	6	50.0	
1999	22	/11	11	50.0	
2000	21	/ 8	13	38.1	
2001	21	14	7	66.7	
2002	25	12	13	48.0	
2003	22	9	13 /	40.9	
2004	29	14	15/	48.3	
2005	28	16	12	57.1	
2006	28	17	1/1	60.7	
2007	41	24	17	58.5	
2008	60	30	30	50.0	
2009	56	26	30	46.4	
2010	47	26	21	55.3	
2011	66	33	33	50.0	
1998-2011	478	246	232	51.5	

subsequent malignancy.

Table 2

Incidence measures by year of diagnosis and gender including DCO cases (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

			Males	Fem.	Males	Fem.	Males	Fem.	Males	Fem.
Year of	Males	Females	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.
diagnosis	n	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	6	6	0.5	0.5	0.4	0.3	0.5	0.4	0.6	0.5
1999	11	11	1.0	0.9	0.6	0.4	0.9	0.7	1.1	0.9
2000	8	13	0.7	1.1	0.4	0.8	0.6	1.0	0.7	1.1
2001	14	7	1.2	0.6	0.9	0.4	1.1	0.5	1.3	0.5
2002	12	13	0.6	0.7	0.4	0.4	0.6	0.6	0.7	0.6
2003	9	13	0.5	0.7	0.3	0.4	0.4	0.5	0.5	0.6
2004	14	15 /	0.7	0.8	0.4	0.5	0.6	0.6	0.7	0.7
2005	16	12 <	0.8	0.6	0.7	0.4	0.8	0.5	0.8	0.6
2006	17	11	0.9	0.5	0.5	0.3	0.7	0.5	0.8	0.5
2007	24	17	1.1	0.7	0.7	0.4	0.9	0.6	1.1	0.7
2008	30	30	1.3	1.3	0.8	0.8	1.1	1.0	1.2	1.2
2009	26	30	1.2	1.3	0.7	0.8	1.0	1.0	1.1	1.2
2010	26	21	1.2	0.9	0.6	0.5	0.9	0.7	1.1	0.8
2011	33	33	1.5	1.4	0.8	0.9	1.1	1.2	1.4	1.3
1998-2011	246	232	1.0	0.9	0.6	0.5	0.8	0.7	1.0	0.8



Munich Cancer Registry 04/02/2013 base\_hBNETE.pdf

Table 3

Age distribution parameters by year of diagnosis (All) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	12	60.1	8.0	49.4	70.9	50.9	51.9	60.3	68.3	69.6
1999	22	65.8	12.2	38.6	81.2	47.0	59.0	68.6	76.7	78.9
2000	21	59.2	15.8	15.8	80.5	44.9	52.5	63.2	71.3	74.9
2001	21	56.2	17,1	17.0	79.8	31.3	41.3	62.2	69.3	70.7
2002	25	63.1	13.4	31.0	82.8	48.2	53.9	67.4	74.9	75.6
2003	22	63.6	10.6	43.9	84.4	49.4	60.1	63.2	72.7	79.5
2004	29	58.8	15.2	27.6	84.1	37.8	47.8	62.6	69.2	78.6
2005	28	51.5	16.6	18.1	82.9	21.7	41.6	52.2	65.4	71.2
2006	28	60.0	15.2	28.7	82.6	35,1	49.9	61.0	71.5	79.5
2007	41	60.0	17.0	18.7	84.2	39.9	47.5	65.8	72.1	79.2
2008	60	64.0	12.3	29.4	88.0	42.5	59.9	65.0	72.0	77.9
2009	56	62.4	11.9	25.9	89.3	48.1	55.7	62.7	70.4	75.5
2010	47	62.8	12.8	15.6	82.0	44.5	54.6	66.0	71.0	75.6
2011	66	62.6	11.8	33.0	82.7	46.7	55.4	63.0	70.8	79.5
1998-2011	478	61.2	13.8	15.6	89.3	41.5	53.5	63.2	71.2	77.0

Table 3a

Age distribution parameters by year of diagnosis (MALES)
(incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	6	57.4	10.0	49.4	70.9	49.4	50.9	51.9	69.6	70.9
1999	11	63.4	13.2	38.6	80.4	45.5	53.5	66.2	74.2	78.9
2000	8	58.7	9.9	44.9	77.6	44.9	53.2	56.6	64.0	77.6
2001	14	56.5	19.5	17.0	79.8	29.8	38.4	65.1	70.7	72.6
2002	12	66.7	10.6	49.8	82.8	53.5	57.3	69.4	74.9	75.4
2003	9	63.5	12.3	49.4	84.4	49.4	53.2	62.7	65.5	84.4
2004	14	58.3	14.6	37.8	80.5	38.9	41.0	60.6	69.2	78.6
2005	16	50.4	16.2	18.1	71.2	21.7	41.0	52.2	66.0	70.1
2006	17	62.3	15.9	28.7	82.6	35.1	56.4	66.5	72.3	80.9
2007	24	61.3	15.9	18.7	80.7	44.2	53.7	65.9	72.1	79.2
2008	30	65.2	12.2	32.3	88.0	47.9	60.2	67.3	72.3	79.6
2009	26	62.0	9.9	30.8	76.7	52.2	55.8	63.0	69.4	71.1
2010	26	63.3	15.5	15.6	82.0	43.8	54.0	69.9	72.7	81.7
2011	33	65.1	12.3	34.4	82.7	46.7	58.0	66.7	74.7	80.5
1998-2011	246	61.7	14.1	15.6	88.0	41.4	53.5	64.5	71.1	79.0

Table 3b

Age distribution parameters by year of diagnosis (FEMALES) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	6	62.8	4.7	56.6	68.7	56.6	59.9	61.8	67.8	68.7
1999	11	68.1	11.2	47.0	81.2	54.6	59.0	71.8	77.6	78.4
2000	13	59.5	19.0	15.8	80.5	29.3	52.5	67.2	72.2	74.9
2001	7	55.6	12,2	38.0	69.3	38.0	41.3	55.5	66.9	69.3
2002	13	59.8	15.3	31.0	76.2	33.6	51.4	65.9	72.8	75.6
2003	13	63.7	9.8	43.9	79.5	49.2	60.4	63.8	72.7	73.0
2004	15	59.3	16.2	27.6	84.1	29.9	47.8	64.9	69.4	73.2
2005	12	52.9	17.7	21.6	82.9	32.2	41.6	52.3	62.3	77.4
2006	11	56.5	14.1	30.4	78.6	40.2	47.3	56.7	68.0	74.3
2007	17	58.3	18.7	22.3	84.2	29.1	43.9	59.7	72.9	81.5
2008	30	62.8	12.4	29.4	79.9	42.5	59.3	64.5	71.7	76.0
2009	30	62.7	13.5	25.9	89.3	47.0	55.6	61.7	71.9	79.3
2010	21	62.3	8.9	39.9	75.8	51.2	60.0	65.3	66.4	71.8
2011	33	60.1	10.8	33.0	82.2	47.3	53.4	61.5	66.7	75.2
1998-2011	232	60.7	13.6	15.8	89.3	41.6	53.6	62.9	71.3	75.8

Table 4

Age distribution by 5-year age group and gender for period 1998-2011 (incl. DCO)

Age at									
diagnosis	Cases			Males			Females		
Years	n	%	Cum.%	n	00	Cum.%	n	%	Cum.%
15-19	5	1.0	1.0	4	1.6	1.6	1	0.4	0.4
20-24	3	0.6	1, 7	/1	0.4	2.0	2	0.9	1.3
25-29	9	1.9	3.6	3	1.2	3.3	6	2.6	3.9
30-34	11	2.3	5.9	/ 5	2.0	5.3	6	2.6	6.5
35-39	11	2.3	8.2	/ 7	2.8	8.1	4	1.7	8.2
40-44	23	4.8	13.0	12	4.9	13.0	11	4.7	12.9
45-49	27	5.6	18.6	10	4.1	/17.1	17	7.3	20.3
50-54	43	9.0	27.6	27	11.0	28.0	16	6.9	27.2
55-59	53	11.1	38.7	22	8.9	37.0	31	13.4	40.5
60-64	79	16.5	55.2	36	14.6	51.6	43	18.5	59.1
65-69	75	15.7	70.9	41	16.7	68.3	34	14.7	73.7
70-74	72	15.1	86.0	41	16.7	85.0	31	13.4	87.1
75-79	40	8.4	94.4	19	7.7	92.7	21	9.1	96.1
80-84	25	5.2	99.6	17	6.9	99.6	8	3.4	99.6
85+	2	0.4	100.0	1	0.4	100.0	1	0.4	100.0
All ages	478	100.0		246	100.0		232	100.0	

Included in the statistics are 26.4% multiple primaries in males and 28.1% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers for period 1998-2011

Age at diagnosis Males Years n					Females DCO rate n=0 %	cancers	Females Prop.all cancers n=129521 %
0- 4 5- 9 10-14 15-19 4 20-24 1 25-29 3 30-34 5 35-39 7 40-44 12 45-49 10 50-54 27 55-59 22 60-64 36 65-69 41 70-74 41 75-79 19 80-84 17 85+ 1	1 2 6 6 4 11 17 16 31 43 34 30 21 8	0.0 0.0 0.3 0.1 0.2 0.3 0.5 0.5 1.6 1.4 2.4 3.0 4.0 2.8 4.2 0.4	0.0 0.0 0.0 0.1 0.1 0.3 0.3 0.2 0.5 0.9 0.9 1.9 2.7 2.3 2.4 2.1 1.0			1.4 0.2 0.4 0.4 0.4 0.2 0.4 0.2 0.2 0.2 0.2	0.4 0.5 0.7 0.3 0.1 0.2 0.2 0.3 0.3 0.3 0.2 0.2
All ages 246	231			0.0	0.0	0.2	0.2
Incidence Raw WS ES BRD-S		1.0 0.6 0.8 1.0	0.9 0.5 0.7 0.8				


The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries for period 1998-2011

MALES

Diagnosis	Observed F	Expected n	SIR	LCL 95%	UCL 95%	EAR	DCO %
C16 Stomach C67 Bladder	2 2	0.3	6.8	0.8	24.4 24.9	31.8 31.9	
Other primaries Not observed	6 0	3.6 2.9	1.7	0.6	3.6	44.3 -54.3	
All mult. primaries	10	7.1	1.4	0.7	2.6	53.7	




# The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 are pooled in category "Other primaries".

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries for period 1998-2011 FEMALES

	Observed Ex	pected		LCL	UCL		DCO
Diagnosis	n /	n	SIR	95%	95%	EAR	%
C33-C34 Lung C50 Breast	3 4	0.4	7.2	1.5	21.0 # 5.6	44.0 37.0	
Other primaries Not observed	5	1.3 2.1	3.9	1.3	9.1 #	63.4 -35.6	20.0
All mult. primaries	12	5.6	2.1	1.1	3.7 #	108.8	8.3



# The occurrence of second malignancy is statistically significant.

Observed second malignancy with count 1 are pooled in category "Other primaries".

## BNET: Bronchopulmonary neuroendocrine tumor (excl. SCLC)





Figure 7. Age distribution and age-specific incidence

## BNET: Bronchopulmonary neuroendocrine tumor (excl. SCLC)



**Figure 7a.** Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).



Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER\*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2012, based on the November 2011 submission. http://www.seer.cancer.gov.

Follow-up year since diagnosis





Figure 8. Cumulative follow-up years depending on time since diagnosis

The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.



#### Average incidence (world standard population) 2003 - 2008: Males




#### Average incidence (world standard population) 2003 - 2008: Females



**Figure 9a.** Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.6/100,000 WS N=103, females 0.5/100,000 WS N=96). Since cancer data are not available in some counties until 2007, the local incidence rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 3 women were identified with newly diagnosed lung neuroend. tumor. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.6/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.1 and 2.2/100,000.

### Standardized incidence ratio (SIR) 2003 - 2008: Males



0.4 0.3 0.2 0.1

**Figure 9b.** Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=103, females N=96). Since cancer data are not available in some counties until 2007, the local SIR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 3 women were identified with newly diagnosed lung neuroend. tumor. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 1.02. Though, the value of this parameter may vary with an underlying probability of 99% between 0.11 and 3.73, and is therefore not statistically striking.

#### **MORTALITY**

Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status, proportion of DCO, deaths among the annual cohorts, and proportion of available death certificates (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

		Prop.				Prop. deaths
	Incident	actively	Prop.		Prop.	with death
Year of	cases	followed	DCO	Deaths	deaths	certific.
diagnosis	n	%	%	/ n /	%	%
1998	12	83.3		5	41.7	100.0
1999	22	100.0		12	54.5	100.0
2000	21	100.0		10	47.6	90.0
2001	21	95.2		13	61.9	100.0
2002	25	96.0		9	36.0	88.9
2003	22	100.0		9	40.9	77.8
2004	29	93.1		11	37.9	100.0
2005	28	89.3		9	32.1	100.0
2006	28	89.3		8	28.6	100.0
2007	41	82.9		19	46.3	100.0
2008	60	71.7		23	38.3	95.7
2009	56	55.4		19	33.9	94.7
2010	47	95.7		20	42.6	95.0
2011	66	81.8		16	24.2	93.8
1998-2011	478	84.3		183	38.3	95.6

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased the same year of cancer diagnosis (incl. DCO)

			Prop.		
			deaths		Prop.
Year of	Incident		with death	Deaths in	deaths in
diagnosis/	cases	Deaths	certific.	same year	same year
death	n	/ n /	%	n	%
1998	12	/5	100.0	2	16.7
1999	22	8	87.5	1	4.5
2000	21	9	100.0	2	9.5
2001	21	6	83.3	/ 1	4.8
2002	25	12	100.0	5	20.0
2003	22	9	100.0	3	13.6
2004	29	10	90.0	2	6.9
2005	28	15	93.3	3	10.7
2006	28	16	100.0	2	7.1
2007	41	17	94.1	6	14.6
2008	60	25	100.0	10	16.7
2009	56	25	96.0	_ 10	17.9
2010	47	27	96.3	7	14.9
2011	66	29	100.0	8	12.1
1998-2011	478	213	96.7	62	13.0

Table 10c

Annual cohorts of deaths, proportion of cancer-related and not cancer-related deaths, and cancer recorded on death certificates (incl. DCO)

(with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

				Prop.	
				cancer	
		Prop.	Prop.	recorded	
		cancer-	not cancer-	on death	
Year of	Deaths	related	related	certificate	
death	n /	8	8	%	
1998	5	100.0		80.0	
1999	5 8	75.0	25.0	100.0	
2000	9	77.8	22.2	88.9	
2001	6	83.3	/16.7/	80.0	
2002	12	83.3	16.7	91.7	
2003	9	88.9	11.1	88.9	
2004	10	80.0	20.0	88.9	
2005	15	73.3	26.7	85.7	
2006	16	68.8	31.3	87.5	
2007	17	70.6	29.4	81.3	
2008	25	80.0	20.0	80.0	
2009	25	96.0	4.0	95.8	
2010	27	85.2	14.8	92.3	
2011	29	82.8	17.2	82.8	
1998-2011	213	81.7	18.3	87.4	

Table 11a  $\begin{tabular}{ll} Means of age at death according to the grouping in Table 10 \\ \hline MALES \end{tabular}$ 

					Age at
		Age at	Age at	Age at	death
		death	death	death	(according
		(all	(cancer-	(not cancer-	to death
Year of	Deaths	causes)	related)	related)	certificate)
death	n	Years	Years	Years	Years
1998	3	67.5	67.5		64.7
1999	4	69.0	69.0		69.0
2000	3	73.7	73.7		73.7
2001	4	61.5	60.2	65.3	62.3
2002	9	68.0	68.6	65.9	68.5
2003	7	67.7	67.2	71.3	67.2
2004	5	59.8	59.8		59.8
2005	10	68.7	68.2	70.7	68.2
2006	13	71.5	74.3	56.1	71.5
2007	11	65.9	64.1	70.6	64.1
2008	18	71.3	71.0	74.2	71.0
2009	18	66.4	66.4		66.1
2010	18	65.5	64.3	71.7	66.0
2011	20	74.2	71.0	87.0	72.0
1998-2011	143	68.6	68.0	72.3	68.3




Table 11b Means of age at death according to the grouping in Table 10 FEMALES

					Age at
		Age at	Age at	Age at	death
		death	death	death	(according
		(all	(cancer-	(not cancer-	to death
Year of	Deaths	causes)	related)	related)	certificate)
death	n	Years	Years	Years	Years
1998	2	74.6	74.6		74.6
1999	4	68.4	77.2	59.5	75.1
2000	6	77.2	76.4	78.7	76.9
2001	2	58.7	58.7		58.7
2002	3	73.2	73.2		73.2
2003	2	73.2	73.2		73.2
2004	5	74.6	74.0	75.5	77.5
2005	5	77.2	76.4	78.2	78.4
2006	3	80.8		80.8	80.4
2007	6	67.0	62.5	76.1	65.1
2008	7	75.7	70.3	83.0	70.3
2009	7	67.9	64.8	86.6	67.9
2010	9	73.3	72.4	80.6	71.7
2011	9/	70.5	69.6	78.2	70.0
1998-2011	70	72.5	70.6	77.5	71.7



Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a  $\begin{tabular}{ll} Mortality measures (cancer-related death) and mortality-incidence-index \\ by year of death \\ \hline MALES \\ \end{tabular}$ 

Year of	Deaths	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	3	0.3	0.50	0.2	0.40	0.2	0.44	0.3	0.50
1999	4	0.4	0.36	0.2	0.32	0.3	0.36	0.4	0.36
2000	3	0.3	0.38	0.1	0.30	0.2	0.36	0.4	0.58
2001	3	0.3	0.21	0.2	0.19	0.2	0.22	0.3	0.21
2002	7	0.4	0.58	0.2	0.55	0.3	0.54	0.4	0.54
2003	6	0.3	0.67	0.2	0.62	0.3	0.69	0.4	0.73
2004	5	0.3	0.36	0.2	0.42	0.3	0.44	0.3	0.39
2005	8	0.4	0.50	0.2	0.33	0.3	0.41	0.5	0.54
2006	11	0.6	0.65	0.3	0.54	0.4	0.67	0.6	0.77
2007	8	0.4	0.33	0.2	0.29	0.3	0.30	0.3	0.30
2008	16	0.7	0.53	0.3	0.45	0.5	0.50	0.7	0.59
2009	18	0.8	0.69	0.4	0.58	0.6	0.60	0.7	0.67
2010	15	0.7	0.58	0.4	0.57	0.5	0.59	0.6	0.55
2011	16	0.7	0.48	0.3	0.41	0.5	0.43	0.7	0.51
1998-2011	123	0.5	0.50	0.3	0.43	0.4	0.47	0.5	0.52

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index by year of death

FEMALES

Year of	Deaths	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	2	0.2	0.33	0.1	0.24	0.1	0.27	0.2	0.38
1999	2	0.2	0.20	0.1	0.15	0.1	0.17	0.2	0.21
2000	4	0.3	0.31	0.1	0.15	0.2	0.20	0.3	0.28
2001	2	0.2	0.29	0.1	0.33	0.2	0.32	0.2	0.35
2002	3	0.2	0.23	0.1	0.16	0.1	0.18	0.1	0.23
2003	2	0.1	0.15	0.0	0.09	0.1	0.10	0.1	0.13
2004	3	0.2	0.20	0.1	0.11	0.1	0.14	0.1	0.17
2005	3	0.2	0.25	0.0	0.12	0.1	0.14	0.1	0.19
2006									
2007	4	0.2	0.24	0.1	0.21	0.1	0.22	0.1	0.22
2008	4	0.2	0.13	0.1	0.09	0.1	0.11	0.1	0.13
2009	6	0.3	0.20	0.1	0.17	0.2	0.17	0.2	0.18
2010	8	0.3	0.38	0.1	0.26	0.2	0.28	0.2	0.32
2011	8	0.3	0.24	0.2	0.18	0.2	0.19	0.3	0.21
1998-2011	51	0.2	0.22	0.1	0.16	0.1	0.17	0.2	0.20

Table 13

Age distribution of age at death (cancer-related) for period 1998-2011 (incl. multiple primaries)

Age at									
death	Cases			Males			Females		
Years	n	%	Cum.%	n	્રે	Cum.%	n	%	Cum.%
40 - 44	6	3.4	3.4	4	3.3	3.3	2	3.9	3.9
45-49	6	3.4	6.9	4	3.3	6.5	2	3.9	7.8
50-54	8	4.6	11.5	8	6.5	13.0			7.8
55-59	12	6.9	18.4	/ 10	8.1	21.1	2	3.9	11.8
60-64	20	11.5	29.9	14	11.4	32.5	6	11.8	23.5
65-69	32	18.4	48.3	23	18.7	51.2	9	17.6	41.2
70-74	37	21.3	69.5	25	20.3	71.5	12	23.5	64.7
75-79	24	13.8	83.3	18	14.6	86.2	6	11.8	76.5
80-84	24	13.8	97.1	14	11.4	97.6	10	19.6	96.1
85+	5	2.9	100.0	3	2.4	100.0	2	3.9	100.0
All ages	174	100.0		123	100.0		51	100.0	

Included in the statistics are 26.4% multiple primaries in males and 28.1% in females.

Table 14

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2011 (incl. multiple primaries)

Age at death		Females	Males Age- spec.		Females Age- spec.		cancers	Females Prop.all cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	%	%
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39			0.0		0.0			
40-44	4	2	0.2		0.1	0.18	0.5	0.2
45-49	4	2	0.2	0.40	0.1	0.12	0.3	0.1
50-54	8		0.5	0.30	0.0		0.3	
55-59	10	2	0.6		0.1		0.2	0.0
60-64	14	6	0.9		0.4	0.14	0.2	0.1
65-69	23	9	1.7		0.6	0.26	0.2	0.1
70-74 75-79	25	12 6	2.4		1.0	0.39	0.2	0.1
75-79 80-84	18 14	10	2.7 3.4		0.6 1.3	0.29 1.25	0.2 0.2	0.1 0.1
85+	3	2	1.1		0.3	2.00	0.2	0.0
0.5+	3	2	1.1	3.00	0.3	2.00	0.0	0.0
All ages	123	51					0.2	0.1
milit ages	123	\					\ 0.2	0.1
Mortality								
Raw			0.5	0.50	0.2	0.22		
WS			0.3	0.43	0.1	0.15		
ES			0.4	0.47	0.1	0.17		
BRD-S			0.5	0.52	0.2	0.20		
PYLL-70								
per 100,000			2.8		0.9			
ES			2.4		0.7			
AYLL-70			10.0		9.2			

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.

Table 15a Multiple primaries in deaths in period 1998-2011 MALES

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n /	%↓	n	<b>←</b> %	n	% →	n	% →
C03-C06 Oral cavity	,1	2.2	1	100.0				
C09-C10 Oropharynx	/2	4.4	1	50.0			1	50.0
C15 Oesophagus	/ 1	2.2	1	100.0				
C16 Stomach	/ 3	6.7	1	33.3	1	33.3	1	33.3
C17 Small intestine	/ 1	2.2			1	100.0		
C18 Colon	/ 2 /	4.4	1	50.0	1	50.0		
C19-C20 Rectum	2	4.4	2	100.0				
C22 Liver	2	4.4			/ 1	50.0	1	50.0
C33-C34 Lung	7	15.6			2	28.6	5	71.4
C43 Malign. melanoma	1	2.2	1	100.0				
C44 Skin others	3	6.7	2	66.7			1	33.3
C48 Peritoneal	1	2.2					1	100.0
C50 Breast	1	2.2	1	100.0			_	
C61 Prostate	6	13.3	4	66.7			2	33.3
C66 Ureter	1	2.2	_				$\overline{1}$	100.0
C67 Bladder	8	17.8	5	62.5	_ 1	12.5	$\sqrt{2}$	25.0
C70-C72 CNS cancer	2	4.4	1	50.0		12.5	1	50.0
C81 Hodgkin lymphoma	<del>-</del>	2.2	1	100.0			_	30.0
coi nodykin tymphoma		۷.۷		100.0				
All mult. primaries	45	100.0	22	48.9	7	15.6	16	35.6




Table 15b  $\label{eq:multiple primaries in deaths in period 1998-2011 FEMALES }$ 

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n /	%↓	n	<b>←%</b>	n	<b>←%</b>	n	<b>←</b> %
C07-C08 Salivary gland	1	3.8	1	100.0				
C09-C10 Oropharynx	/1	3.8	1	100.0				
C18 Colon	/ 1	3.8					1	100.0
C32 Larynx	/ 1	3.8	1	100.0				
C33-C34 Lung	5	19.2			3	60.0	2	40.0
C43 Malign. melanoma	/ 1 /	3.8	1	100.0				
C50 Breast	4	15.4	4	100.0				
C53 Cervix uteri	1	3.8			/ 1	100.0		
C56 Ovary	1	3.8	1	100.0				
C64 Kidney	3	11.5	2	66.7	1	33.3		
C70-C72 CNS cancer	3	11.5			1	33.3	2	66.7
C73 Thyroid	1	3.8			1	100.0		
C74-C80 Cancer others	1	3.8	1	100.0				
C90 Mult. myeloma	1	3.8					1	100.0
C91-C96 Leukaemia	1	3.8					1	100.0
All mult. primaries	26	100.0	12	46.2	7	26.9	7	26.9




Table 16

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2011

(Singular primaries only \*)

Age at death		Females			Females Age- spec.		cancers	Females Prop.all cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	%	%
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39			0.0		0.0			
40-44	4	1	0.2	0.40	0.0	0.10	0.6	0.1
45-49	4	2	0.2	0.44	0.1	0.12	0.3	0.1
50-54	6		0.4	0.23	0.0		0.2	
55-59	10	2	0.6	0.50	0.1	0.08	0.2	0.1
60-64	12	3	0.8	0.40	0.2	0.09	0.2	0.1
65-69	21	6	1.5	0.55	0.4	0.22	0.2	0.1
70-74	18	7	1.7		0.6	0.33	0.2	0.1
75-79	11/	/5	1.6	0.73	0.5	0.31	0.1	0.1
80-84	8	8	2.0	0.89	1.0	1.00	0.1	0.1
85+	2		0.7	2.00	0.0		0.0	
7.7.7	0.6	2.4					0.0	0 1
All ages	96	34					0.2	0.1
Mortality								
Raw			0.4	0.48	0.1	0.18		
WS			0.1	0.41	0.1	0.10		
ES			0.3		0.1	0.14		
BRD-S			0.3	0.49	0.1			
BRD B			0.1	0.15	0.1	0.10		
PYLL-70								
per 100,000			2.5		0.6			
ES			2.2		0.5			
AYLL-70			10.0		9.6			

<sup>\*</sup> See corresponding tables with multiple primaries.


Table 17


Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2011

(Single primaries only \*)

Age at			Males Age-		Females Age-		Males	Females Prop.all
death	Maleg	Females			spec.		cancers	cancers
Years	n	n	_ /	MI-index	-	MT-index		%
ICCID			morcar.	111 1110011		111 1110011	Ü	Ü
0 - 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39			0.0		0.0			
40-44	4	1	0.2		0.0	0.10	0.6	0.1
45-49	3	2	0.2	0.33	0.1	0.13	0.2	0.1
50-54	6		0.4		0.0		0.3	
55-59	9	2	0.6		0.1	0.09	0.2	0.1
60-64	9	2	0.6		0.1	0.06	0.2	0.0
65-69	21	4	1.5		0.3	0.17	0.3	0.1
70-74	16	6	1.6	0.67	0.5	0.30	0.2	0.1
75-79	9	5	1.3		0.5	0.33	0.1	0.1
80-84	7 2	8	1.7		1.0	1.00	0.1	0.1
85+	۷		0.7	2.00	0.0		0.0	
All ages	86	30					0.2	0.1
Mortality								
Raw			0.3		0.1	0.17		
WS			0.2		0.0	0.11		
ES			0.3		0.1	0.13		
BRD-S			0.3	0.46	0.1	0.16		
PYLL-70								
per 100,000			2.3		0.5			
ES			2.0		0.5			
AYLL-70			9.9		11.1			

<sup>\*</sup> See corresponding tables with multiple primaries.






**Figure 18.** Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).


The difference between age at diagnosis (Table 3) and age at lung neuroend. tumor-related death (see Table 10) should be considered.



#### Average mortality (world standard population) 2003 - 2008: Males




#### Average mortality (world standard population) 2003 - 2008: Females



**Figure 19a.** Map of cancer mortality (world standard population) by county averaged for period 2003 to 2008. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.2/100,000 WS N=51, females 0.1/100,000 WS N=15). Since cancer data are not available in some counties until 2007, the local mortality rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women died from lung neuroend. tumor. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.0/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 0.4/100,000.

#### Standardized mortality ratio (SMR) 2003 - 2008: Males



**Figure 19b.** Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=51, females N=15). Since cancer data are not available in some counties until 2007, the local SMR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women died from lung neuroend. tumor. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 2.27. Though, the value of this parameter may vary with an underlying probability of 99% between 0.01 and 16.89, and is therefore not statistically striking.

#### **Statistical Notes**

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

#### 1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the tumor-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

**3. Single primary** (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

#### **Shortcuts**

AYLL-70 Average years of life lost prior to age 70 given a person dies before that age

BRD-S German standard population

DCO Death certificate only EAR Excess absolute risk

= excess cancer cases (O - E) per 10,000 person-years

ES European standard population (old) FRG Federal Republic of Germany

GEKID Association of Population-based Cancer Registries in Germany

(Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)

LCL Lower confidence limit

MI-index Ratio between mortality and incidence

MCR Munich Cancer Registry (Tumorregister München)

PYLL-70 Potential years of life lost prior to age 70 given a person dies before that age

SEER Surveillance, Epidemiology, and End Results (USA)

SIR Standardized incidence ratio
SMR Standardized mortality ratio
UCL Upper confidence limit
WS World standard population

#### **Recommended Citation**

Munich Cancer Registry. Baseline statistics BNET: Lung neuroend. tumor [Internet]. 2013 [updated 2013 Apr 2; cited 2013 Jun 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base\_hBNETE.pdf

#### Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

#### **Disclaimer**

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

# Index of figures and tables

I.	Page
Pts cohorts, DCO, mult. prim., follow-up / yr	4
Gender distribution by year of diagnosis	5
Incidence by year of diagnosis	6
Age distribution parameters by year of diagnosis	7
Age distribution by 5-year age group and gender	9
Age-specific incidence and DCO rate	10
Standardized incidence ratio of second primaries	11
Age distribution and age-specific incidence (chart)	13
Age-specific incidence internationally (chart)	14
Cumulative follow-up years (chart)	15
Map of cancer incidence (WS) by county (chart)	16
Standardized incidence ratio (SIR) by county (chart)	17
Pts incident cohorts and mortality / yr	18
Incidence and mortality by year of diagnosis	19
Cancer-related deaths, death certification available / yr	20
Means of age at death / yr	21
Mortality by year of death	23
Distribution of age at death	24
Age-specific mortality	25
Multiple primaries in deaths	26
Age-specific mortality (first primaries)	28
Age-specific mortality (single primaries)	29
Age distribution and age-specific mortality (chart)	30
Map of cancer mortality (WS) by county (chart)	31
Standardized mortality ratio (SMR) by county (chart)	32
	Pts cohorts, DCO, mult. prim., follow-up / yr Gender distribution by year of diagnosis Incidence by year of diagnosis Age distribution parameters by year of diagnosis Age distribution by 5-year age group and gender Age-specific incidence and DCO rate Standardized incidence ratio of second primaries Age distribution and age-specific incidence (chart) Age-specific incidence internationally (chart) Cumulative follow-up years (chart) Map of cancer incidence (WS) by county (chart) Standardized incidence ratio (SIR) by county (chart) Pts incident cohorts and mortality / yr Incidence and mortality by year of diagnosis Cancer-related deaths, death certification available / yr Means of age at death / yr Mortality by year of death Distribution of age at death Age-specific mortality Multiple primaries in deaths Age-specific mortality (first primaries) Age-specific mortality (single primaries) Age distribution and age-specific mortality (chart) Map of cancer mortality (WS) by county (chart)